The number needed to treat to prevent mortality and cirrhosis-related complications among patients with cirrhosis and HCV genotype 1 infection

Journal of Viral Hepatitis

Volumn 21, Issue 8, 2014, Pages 568-577

  Van Der Meer, A J ^a   Veldt, B J ^a   Feld, J J ^b   Wedemeyer, H ^c   Dufour, J F ^d   Lammert, F ^e   Duarte Rojo, A ^b   Manns, M P ^c   Zeuzem, S ^f   Hofmann, W P ^f   De Knegt, R J ^a   Hansen, B E ^a   Janssen, H L A ^a,b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b TORONTO WESTERN HOSPITAL   (Canada)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d UNIVERSITY OF BERN   (Switzerland)

^e SAARLAND UNIVERSITY   (Germany)

^f UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

chronic hepatitis C; cirrhosis; genotype 1; mortality; number needed to treat

Indexed keywords

INTERFERON; PEGINTERFERON; RIBAVIRIN; ANTIVIRUS AGENT;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CAUSE OF DEATH; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; EVENT FREE SURVIVAL; FEMALE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORBIDITY; NUMBERS NEEDED TO TREAT; PRIORITY JOURNAL; CLASSIFICATION; CLINICAL TRIAL; COMPLICATION; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; INTERNATIONAL COOPERATION; ISOLATION AND PURIFICATION; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; SURVIVAL;

ADULT; ANTIVIRAL AGENTS; COHORT STUDIES; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERNATIONAL COOPERATION; LIVER CIRRHOSIS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS;

EID: 84903819709     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12185     Document Type: Article

References (42)

1. Poynard T, Bedossa P, Opolon P,. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349 (9055): 825-832. (Pubitemid 27129209)
2. Buti M, San Miguel R, Brosa M, et al,. Estimating the impact of hepatitis C virus therapy on future liver-related morbidity, mortality and costs related to chronic hepatitis C. J Hepatol 2005; 42 (5): 639-645.
3. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW,. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010; 138 (2): 513-521.
4. Bruno S, Stroffolini T, Colombo M, et al,. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007; 45 (3): 579-587. (Pubitemid 46453759)
5. Cardoso AC, Moucari R, Figueiredo-Mendes C, et al,. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol 2010; 52 (5): 652-657.
6. Morgan TR, Ghany MG, Kim HY, et al,. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology 2010; 52 (3): 833-844.
7. Van der Meer AJ, Veldt BJ, Feld JJ, et al,. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308 (24): 2584-2593.
8. Hadziyannis SJ, Sette H Jr, Morgan TR, et al,. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140 (5): 346-355.
9. Manns MP, McHutchison JG, Gordon SC, et al,. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358 (9286): 958-965. (Pubitemid 32913521)
10. Blatt LM, Mutchnick MG, Tong MJ, et al,. Assessment of hepatitis C virus RNA and genotype from 6807 patients with chronic hepatitis C in the United States. J Viral Hepat 2000; 7 (3): 196-202. (Pubitemid 30337615)
11. Trepo C, Pradat P,. Hepatitis C virus infection in Western Europe. J Hepatol 1999; 31 (Suppl. 1): 80-83. (Pubitemid 30002696)
12. Vezali E, Aghemo A, Colombo M,. A review of the treatment of chronic hepatitis C virus infection in cirrhosis. Clin Ther 2010; 32 (13): 2117-2138.
13. Heathcote EJ, Shiffman ML, Cooksley WG, et al,. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000; 343 (23): 1673-1680.
14. Jacobson IM, McHutchison JG, Dusheiko G, et al,. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364 (25): 2405-2416.
15. Poordad F, McCone J Jr, Bacon BR, et al,. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364 (13): 1195-1206.
16. Cook RJ, Sackett DL,. The number needed to treat: a clinically useful measure of treatment effect. BMJ 1995; 310 (6977): 452-454.
17. Laupacis A, Sackett DL, Roberts RS,. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 1988; 318 (26): 1728-1733.
18. Bruix J, Sherman M,. Management of hepatocellular carcinoma. Hepatology 2005; 42 (5): 1208-1236. (Pubitemid 43112690)
19. Altman DG, Andersen PK,. Calculating the number needed to treat for trials where the outcome is time to an event. BMJ 1999; 319 (7223): 1492-1495.
20. Bobbio M, Demichelis B, Giustetto G,. Completeness of reporting trial results: effect on physicians' willingness to prescribe. Lancet 1994; 343 (8907): 1209-1211. (Pubitemid 24147560)
21. Forrow L, Taylor WC, Arnold RM,. Absolutely relative: how research results are summarized can affect treatment decisions. Am J Med 1992; 92 (2): 121-124.
22. Naylor CD, Chen E, Strauss B,. Measured enthusiasm: does the method of reporting trial results alter perceptions of therapeutic effectiveness? Ann Intern Med 1992; 117 (11): 916-921.
23. Ghany MG, Lok AS, Everhart JE, et al,. Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C. Gastroenterology 2010; 138 (1): 136-146.
24. Nkontchou G, Ziol M, Aout M, et al,. HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis. J Viral Hepat 2011; 18 (10): e516-e522.
25. Probst A, Dang T, Bochud M, Egger M, Negro F, Bochud PY,. Role of hepatitis C virus genotype 3 in liver fibrosis progression-a systematic review and meta-analysis. J Viral Hepat 2011; 18 (11): 745-759.
26. de Lemos ML,. NNT for studies with long-term follow-up. CMAJ 2005; 172 (5): 613; author reply -5.
27. Bourliere M, Wendt A, Fontaine H, Hezode C, Pol S, Bronowicki JP,. How to optimize HCV therapy in genotype 1 patients with cirrhosis. Liver Int 2013; 33 (Suppl. 1): 46-55.
28. Williams IT, Bell BP, Kuhnert W, Alter MJ,. Incidence and transmission patterns of acute hepatitis C in the United States, 1982-2006. Arch Intern Med 2011; 171 (3): 242-248.
29. Corpechot C, Barbu V, Wendum D, et al,. Hypoxia-induced VEGF and collagen I expressions are associated with angiogenesis and fibrogenesis in experimental cirrhosis. Hepatology 2002; 35 (5): 1010-1021. (Pubitemid 34453998)
30. Poordad F, Lawitz E, Kowdley KV, et al,. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med 2013; 368 (1): 45-53.
31. Kowdley KV, Lawitz E, Crespo I, et al,. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet 2013; 381 (9883): 2100-2107.
32. Gane EJ, Stedman CA, Hyland RH, et al,. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013; 368 (1): 34-44.
33. Fontaine H, Hezode C, Dorival C, et al,. SVR12 rates and safety of triple therapy including telaprevir or boceprevir in 221 cirrhotic non responders treated in the French early access program (ANRS CO20-CUPIC). J Hepatol 2013; 58 (Suppl. 1): S27.
34. Fattovich G, Giustina G, Degos F, et al,. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997; 112 (2): 463-472. (Pubitemid 27078833)
35. Valla DC, Chevallier M, Marcellin P, et al,. Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment. Hepatology 1999; 29 (6): 1870-1875. (Pubitemid 29247063)
36. Di Bisceglie AM, Shiffman ML, Everson GT, et al,. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 2008; 359 (23): 2429-2441.
37. Bruix J, Poynard T, Colombo M, et al,. Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C. Gastroenterology 2011; 140 (7): 1990-1999.
38. Christensen PM, Kristiansen IS,. Number-needed-to-treat (NNT)-needs treatment with care. Basic Clin Pharmacol Toxicol 2006; 99 (1): 12-16.
39. Hildebrandt M, Vervolgyi E, Bender R,. Calculation of NNTs in RCTs with time-to-event outcomes: a literature review. BMC Med Res Methodol 2009; 9: 21.
40. Suissa D, Brassard P, Smiechowski B, Suissa S,. Number needed to treat is incorrect without proper time-related considerations. J Clin Epidemiol 2012; 65 (1): 42-46.
41. Bender R,. Number Needed to Treat. In:, Armitage P, Colton T, eds. Encyclopedia of Biostatistics, 6. 2nd edn. Chichester: John Wiley & Sons, 2005: 3752-3761.
42. Kristiansen IS, Gyrd-Hansen D, Nexoe J, Nielsen JB,. Number needed to treat: easily understood and intuitively meaningful? Theoretical considerations and a randomized trial J Clin Epidemiol 2002; 55 (9): 888-892. (Pubitemid 35246559)